ResearcherActive in the last 2 years

Chaoxing Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0299-3312; OpenAlex author ID A5020537743, A5130912191. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival. Co-author DOI 10.1093/oncolo/oyag209 ↗
Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanced Pancreatic Cancer. Co-author DOI 10.12669/pjms.38.1.4150 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Lixuan Chen · 1 shared paper, 2026 · strength 0.50
- Paper Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free … DOI 10.1093/oncolo/oyag209 ↗
Ya-jing Zhang · 1 shared paper, 2022 · strength 0.20
- Paper Clinical efficacy evaluation of Erlotinib Combined with Concurrent Chemoradiotherapy in the treatment of locally advanc… DOI 10.12669/pjms.38.1.4150 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.